# Chemed Corp: Form 10-Q for the period ended Mar 31, 2021

- Company: [Chemed Corp](/companies/che.md) (CIK 19584)
- Form: 10-Q
- Filed: 2021-04-30
- Accepted by EDGAR: Apr 30, 2021, 09:15 ET
- Period: 2021-03-31
- Accession: 0000019584-21-000009
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/19584/000001958421000009/che-20210331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/19584/000001958421000009/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2021-01-01 to 2021-03-31 | $340.5m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2021-01-01 to 2021-03-31 | $91.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-01-01 to 2021-03-31 | $80.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-01-01 to 2021-03-31 | $381.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-01-01 to 2021-03-31 | $18.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-01-01 to 2021-03-31 | $65.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-01-01 to 2021-03-31 | $4.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-01-01 to 2021-03-31 | $4.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-01-01 to 2021-03-31 | 16,310,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2021-01-01 to 2021-03-31 | $106.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2021-01-01 to 2021-03-31 | $17.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2021-01-01 to 2021-03-31 | $5.4m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2021-01-01 to 2021-03-31 | $41.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-03-31 | $210.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-03-31 | $347.0m | us-gaap:AssetsCurrent |
| Total assets | at 2021-03-31 | $1.46bn | us-gaap:Assets |
| Current liabilities | at 2021-03-31 | $290.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-03-31 | $529.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-03-31 | $928.9m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2021-03-31 | 15,950,435 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 30,786 characters.

### Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results (in thousands except per share amounts):

|  | Three months ended March 31, 2021 | 2020 |
| --- | ---: | ---: |
| Service revenues and sales | **$527,360** | $515,798 |
| Net income | **$65,400** | $55,891 |
| Diluted EPS | **$4.01** | $3.38 |
| Adjusted net income | **$72,370** | $60,715 |
| Adjusted diluted EPS | **$4.44** | $3.68 |
| Adjusted EBITDA | **$108,519** | $93,029 |
| Adjusted EBITDA as a % of revenue | **20.6%** | 18.0% |

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 27-28.

For the three months ended March 31, 2021, the increase in consolidated service revenues and sales was driven by an 18.9% increase at Roto-Rooter offset by a 6.5% decrease at VITAS. The increase in service revenues at Roto-Rooter was driven by an increase in all major service lines for residential customers. The decrease in service revenues at VITAS is comprised primarily of a 7.1% decrease in days-of-care offset by a geographically weighted average Medicare reimbursement rate increase (including the suspension of sequestration on May 1, 2020) of approximately 2.8%. Acuity mix shift had a net impact of reducing revenue approximately $9.1 million, or 2.7% in the quarter when compared to the prior year revenue and level-of-care mix. The combination of a lower Medicare cap and other contra revenue changes offset a portion of the revenue decline by approximately 50 basis points. See page 29 for additional VITAS operating metrics.

The current COVID-19 pandemic did have a material impact on our business operations, results of operations, cash flow and financial position as of and for the three months ended March 31, 2021 and 2020, respectively. We are closely monitoring the impact of the pandemic on all aspects of our business including impacts to employees, customers, patients, suppliers and vendors. The Company’s two operating subsidiaries have been categorized as critical infrastructure businesses and are not currently materially limited by federal, state or local regulations that restrict movement or operating ability.

The length and severity of the pandemic, coupled with related governmental actions including relief acts and actions relating to our workforce at federal, state and local levels, and underlying economic disruption will determine the ultimate short-term and long-term impact to our business operations and financial results. We are unable to predict the myriad of possible issues that could arise or the ultimate effect to our businesses as a result of the unknown short, medium and long-term impacts that the pandemic will have on the United States economy and society as a whole.

Historically, Chemed earnings guidance has been developed using previous years’ key operating metrics which are then modeled and projected out for the calendar year. Critical within these projections is the understanding of traditional patterned correlations among key operating metrics. Once we complete this phase of our projected operating results, we would then modify the projections for the timing of price increases, changes in commission structure, wages, marketing programs and a variety of continuous improvement initiatives that our business segments plan on executing over the coming year. This modeling exercise also takes into consideration anticipated industry and macro-economic issues outside of management’s control but are somewhat predictable in terms of timing and impact on our business segments’ operating results.

The pandemic has made accurate modeling and providing meaningful earnings guidance for Chemed exceptionally challenging. Federal, state and local government authorities are forced to make swift decisions within our healthcare system, labor pools and general economy. These governmental decisions have the potential for an immediate and material impact on VITAS and Roto-Rooter operating results. We anticipate providing updated 2021 earnings guidance in July of 2021 as part of the June 30, 2021 earnings press release. We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

### Financial Condition

### Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2020 to March 31, 2021 include the following:

A $22.1 million decrease in accounts receivable due to timing of receipts.

A $15.3 million increase in income taxes due to timing of payments.

A $17.4 million decrease in accrued compensation due to the payments of cash bonuses in the first quarter of 2021.

An $8.5 million decrease in accrued legal as a result of the payments of two legal settlements.

A $53.7 million increase in treasury stock due mainly to stock repurchases.

Net cash provided by operating activities increased $17.4 million from March 31, 2020 to March 31, 2021. The main drivers of the increase are an increase in net income and a decrease in accounts receivable. Significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $40.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two year period, as cash flow variations in one year are offset in the following year.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

On June 20, 2018, we signed the Fourth Amended and Restated Credit Agreement (“2018 Credit Agreement”). Terms of the 2018 Credit Agreement consist of a five year, $450 million revolving credit facility and a $150 million expansion feature, which may consist of term loans or additional revolving commitments. The revolving credit facility has a five year maturity with principal payments due at maturity. The interest rate at the inception of the agreement was LIBOR plus 100 basis points. The 2018 Credit Agreement has a floating interest rate that is generally LIBOR plus a tiered additional rate which varies based on our current leverage ratio. We have no debt outstanding under the 2018 Credit Agreement as of March 31, 2021.

We have issued $37.9 million in standby letters of credit as of March 31, 2021, mainly for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of March 31, 2021, we have approximately $412.1 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

### Commitments and Contingencies

Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of March 31, 2021 and anticipate remaining in compliance throughout the foreseeable future.

We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 10 in the Notes to the Consolidated Financial Statements in Item 1 above for a description of current material legal matters.

### Results of Operations

### Three months ended March 31, 2021 versus 2020 - Consolidated Results

Our service revenues and sales for the first quarter of 2021 increased 2.2% versus services and sales revenues for the first quarter of 2020. Of this increase, a $33.7 million increase was attributable to Roto-Rooter offset by a $22.1 million decrease attributable to VITAS. The following chart shows the components of revenue by operating segment (in thousands):

| VITAS | Three months ended March 31, 2021 | 2020 |
| --- | ---: | ---: |
| Routine homecare | **$263,754** | $271,762 |
| Continuous care | **27,349** | 40,555 |
| General inpatient | **29,156** | 32,482 |
| Other | **2,938** | 3,147 |
| Medicare cap adjustment | **(1,500)** | (2,500) |
| Room and board - net | **(2,665)** | (3,381) |
| Implicit price concessions | **(3,244)** | (4,149) |
| Roto-Rooter |  |  |
| Drain cleaning - short term core | **61,756** | 54,020 |
| Plumbing - short term core | **41,313** | 36,794 |
| Subtotal | **103,069** | 90,814 |
| Excavation - short term core | **51,993** | 43,060 |
| Water restoration | **37,435** | 29,246 |
| Contractor operations | **18,760** | 16,228 |
| Outside franchisee fees | **1,327** | 1,190 |
| Other - short term core | **288** | 550 |
| Other | **3,945** | 3,534 |
| Implicit price concessions | **(5,245)** | (6,740) |
| Total | **$527,360** | $515,798 |

Days of care at VITAS during the quarter ended March 31 were as follows:

|  | Days of Care 2021 | 2020 | Increase/(Decrease) Percent |
| --- | ---: | ---: | ---: |
| Routine homecare | **1,329,892** | 1,364,746 | (2.6) |
| Nursing home | **232,783** | 303,374 | (23.3) |
| Respite | **4,840** | 6,692 | (27.7) |
| Subtotal routine homecare and respite | **1,567,515** | 1,674,812 | (6.4) |
| Continuous care | **27,674** | 32,348 | (14.4) |
| General inpatient | **29,300** | 41,373 | (29.2) |
| Total days of care | **1,624,489** | 1,748,533 | (7.1) |

The decrease in service revenues at VITAS is comprised primarily of a 7.1% decline in days-of-care offset by a geographically weighted average Medicare reimbursement rate increase (including the suspension of sequestration on May 1, 2020) of approximately 2.8%. Acuity mix shift had a net impact of reducing revenue approximately $9.1 million, or 2.7% in the quarter when compared to the prior year revenue and level-of-care mix. The combination of a lower Medicare cap and other contra revenue changes offset a portion of the revenue decline by approximately 50 basis points.

The increase in plumbing revenues for the first quarter of 2021 versus 2020 is attributable to a 17.1% increase in job count offset by a 4.8% decrease in price and service mix shift. The increase in excavation revenues for the first quarter of 2021 versus 2020 is attributable to a 22.1% increase in job count offset by a 1.4% decrease in price and service mix shift. Drain cleaning revenues for the first quarter of 2021 versus 2020 reflect a 4.8% increase in price and service mix shift and a 9.5% increase in job count. Water restoration revenue increased for the first quarter of 2021 versus 2020 due to a 10.2% increase in job count and an 17.8% increase in price and service mix shift. Contractor operations increased 15.6% mainly due to their continued expansion into water restoration. The increase in job count for all service lines was driven by residential customers.

The consolidated gross margin was 35.4% in the first quarter of 2021 as compared with 31.8% in the first quarter of 2020. On a segment basis, VITAS’ gross margin was 24.4% in the first quarter of 2021 as compared with 23.2%, in the first quarter of 2020. The increase is primarily due to improved labor costs. The Roto-Rooter segment’s gross margin was 51.9% for the first quarter of 2021 as compared with 48.1% in the first quarter of 2020 primarily due to increased revenue and improved labor costs.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

|  | Three months ended March 31, 2021 | 2020 |
| --- | ---: | ---: |
| SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts | **$86,668** | $78,334 |
| Impact of market value adjustments related to assets held in deferred compensation trusts | **3,038** | (9,572) |
| Long-term incentive compensation | **1,893** | 1,821 |
| Total SG&A expenses | **$91,599** | $70,583 |

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first quarter of 2021 were up 10.6% when compared to the first quarter of 2020. This increase was mainly a result of the increase in variable selling and general administrative expenses and increased bonus expense at Roto-Rooter caused by increased revenue.

Depreciation for the first quarter of 2021 increased 2.9% when compared to the first quarter of 2020 primarily due to new equipment purchased at Roto-Rooter.

Amortization for the first quarter of 2021 increased 1.3% when compared to the first quarter of 2020. Quarterly amortization of intangible assets is mainly driven by two Roto-Rooter franchise acquisitions completed in 2019. The total purchase price of these acquisitions was $138.0 million. As part of the purchase price allocation, approximately $59.2 million was determined to be the value of reacquired franchise rights which are being amortized over the remaining life of each franchise agreement. The average remaining life on the reacquired franchise agreements was approximately seven years. Quarterly amortization of reacquired franchise rights for these two acquisitions is approximately $2.0 million ($8.1 million annualized through 2026). This contrasts to quarterly franchise fees historically collected from these two franchisees of approximately $470,000 ($1.9 million annualized).

Other income – net comprise (in thousands):

|  | Three months ended March 31, 2021 | 2020 |
| --- | ---: | ---: |
| Market value adjustment on assets held in deferred compensation trusts | **$3,038** | $(9,572) |
| Interest income | **92** | 109 |
| Other | **472** | (3) |
| Total other income/(expense) - net | **$3,602** | $(9,466) |

Our effective tax rate reconciliation is as follows (in thousands):

|  | Three months ended March 31, 2021 | 2020 |
| --- | ---: | ---: |
| Income tax provision calculated at the statutory federal rate | **$17,569** | $14,474 |
| Stock compensation tax benefits | **(3,452)** | (4,553) |
| State and local income taxes | **2,956** | 2,377 |
| Other--net | **1,189** | 733 |
| Income tax provision | **$18,262** | $13,031 |
| Effective tax rate | 21.8% | 18.9% |

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

| VITAS | Three months ended March 31, 2021 | 2020 |
| --- | ---: | ---: |
| Direct costs related to COVID-19 | **$(1,308)** | $(726) |
| Medicare cap sequestration adjustment | **-** | (503) |
| Roto-Rooter |  |  |
| Amortization of reacquired franchise agreements | **(1,729)** | (1,729) |
| Direct costs related to COVID-19 | **(407)** | (633) |
| Corporate |  |  |
| Excess tax benefits on stock compensation | **3,238** | 4,553 |
| Stock option expense | **(5,066)** | (4,190) |
| Long-term incentive compensation | **(1,670)** | (1,596) |
| Direct costs related to COVID-19 | **(28)** | - |
| Total | **$(6,970)** | $(4,824) |

### Three months ended March 31, 2021 versus 2020 - Segment Results

Net income/(loss) for the first quarter of 2021 versus the first quarter of 2020 by segment (in thousands):

|  | Three months ended March 31, 2021 | 2020 |
| --- | ---: | ---: |
| VITAS | **$40,770** | $41,279 |
| Roto-Rooter | **37,177** | 24,322 |
| Corporate | **(12,547)** | (9,710) |
|  | **$65,400** | $55,891 |

VITAS’ after-tax earnings decreased due to lower revenue. After-tax earnings as a percent of revenue at VITAS in the first quarter of 2021 was 12.9% as compared to 12.2% in the first quarter of 2020.

Roto-Rooter’s net income was impacted in 2021 compared to 2020 primarily by higher revenue and improved labor costs. After-tax earnings as a percent of revenue at Roto-Rooter in the first quarter of 2021 was 17.6%, as compared to 13.7% in the first quarter of 2020.

After-tax Corporate expenses for 2021 increased 29.2% when compared to 2020 due mainly to a $1.3 million decrease in the excess tax benefits on stock compensation.

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENTS OF INCOME*

*FOR THE THREE MONTHS ENDED MARCH 31, 2021*

*(in thousands)(unaudited)*

| 2021 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Service revenues and sales** | **$315,788** | **$211,572** | **$-** | **$527,360** |
| **Cost of services provided and goods sold** | **238,667** | **101,806** | **-** | **340,473** |
| **Selling, general and administrative expenses** | **22,090** | **53,322** | **16,187** | **91,599** |
| **Depreciation** | **5,338** | **6,353** | **24** | **11,715** |
| **Amortization** | **18** | **2,492** | **-** | **2,510** |
| **Other operating expense** | **502** | **120** | **-** | **622** |
| **Total costs and expenses** | **266,615** | **164,093** | **16,211** | **446,919** |
| **Income/(loss) from operations** | **49,173** | **47,479** | **(16,211)** | **80,441** |
| **Interest expense** | **(42)** | **(89)** | **(250)** | **(381)** |
| **Intercompany interest income/(expense)** | **4,525** | **1,620** | **(6,145)** | **-** |
| **Other income—net** | **533** | **31** | **3,038** | **3,602** |
| **Income/(expense) before income taxes** | **54,189** | **49,041** | **(19,568)** | **83,662** |
| **Income taxes** | **(13,419)** | **(11,864)** | **7,021** | **(18,262)** |
| **Net income/(loss)** | **$40,770** | **$37,177** | **$(12,547)** | **$65,400** |
| **(a) The following amounts are included in net income (in thousands):** |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **Pretax benefit/(cost):** |  |  |  |  |
| **Stock option expense** | **$-** | **$-** | **$(6,106)** | **$(6,106)** |
| **Amortization of reacquired franchise agreements** | **-** | **(2,352)** | **-** | **(2,352)** |
| **Direct costs related to COVID-19** | **(1,753)** | **(553)** | **(38)** | **(2,344)** |
| **Long-term incentive compensation** | **-** | **-** | **(1,893)** | **(1,893)** |
| **Total** | **$(1,753)** | **$(2,905)** | **$(8,037)** | **$(12,695)** |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **After-tax benefit/(cost):** |  |  |  |  |
| **Stock option expense** | **$-** | **$-** | **$(5,066)** | **$(5,066)** |
| **Direct costs related to COVID-19** | **(1,308)** | **(407)** | **(28)** | **(1,743)** |
| **Amortization of reacquired franchise agreements** | **-** | **(1,729)** | **-** | **(1,729)** |
| **Long-term incentive compensation** | **-** | **-** | **(1,670)** | **(1,670)** |
| **Excess tax benefits on stock compensation** | **-** | **-** | **3,238** | **3,238** |
| **Total** | **$(1,308)** | **$(2,136)** | **$(3,526)** | **$(6,970)** |

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENTS OF INCOME*

*FOR THE THREE MONTHS ENDED MARCH 31, 2020*

*(in thousands)(unaudited)*

| 2020 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $337,916 | $177,882 | $- | $515,798 |
| Cost of services provided and goods sold | 259,429 | 92,316 | - | 351,745 |
| Selling, general and administrative expenses | 22,269 | 46,282 | 2,032 | 70,583 |
| Depreciation | 5,474 | 5,878 | 36 | 11,388 |
| Amortization | 18 | 2,459 | - | 2,477 |
| Other operating expenses | 114 | 128 | - | 242 |
| Total costs and expenses | 287,304 | 147,063 | 2,068 | 436,435 |
| Income/(loss) from operations | 50,612 | 30,819 | (2,068) | 79,363 |
| Interest expense | (45) | (102) | (828) | (975) |
| Intercompany interest income/(expense) | 4,386 | 1,349 | (5,735) | - |
| Other income/(expense)—net | 65 | 40 | (9,571) | (9,466) |
| Income/(expense) before income taxes | 55,018 | 32,106 | (18,202) | 68,922 |
| Income taxes | (13,739) | (7,784) | 8,492 | (13,031) |
| Net income/(loss) | $41,279 | $24,322 | $(9,710) | $55,891 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(5,045) | $(5,045) |
| Amortization of reacquired franchise agreements | - | (2,352) | - | (2,352) |
| Direct costs related to COVID-19 | (973) | (861) | - | (1,834) |
| Long-term incentive compensation | - | - | (1,821) | (1,821) |
| Medicare cap sequestration adjustment | (675) | - | - | (675) |
| Total | $(1,648) | $(3,213) | $(6,866) | $(11,727) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(4,190) | $(4,190) |
| Amortization of reacquired franchise agreements | - | (1,729) | - | (1,729) |
| Long-term incentive compensation | - | - | (1,596) | (1,596) |
| Direct costs related to COVID-19 | (726) | (633) | - | (1,359) |
| Medicare cap sequestration adjustment | (503) | - | - | (503) |
| Excess tax benefits on stock compensation | - | - | 4,553 | 4,553 |
|  | $(1,229) | $(2,362) | $(1,233) | $(4,824) |

*Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the three months ended March 31, 2021 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $40,770 | **$37,177** | **$(12,547)** | **$65,400** |
| **Add/(deduct):** |  |  |  |  |
| **Interest expense** | **42** | **89** | **250** | **381** |
| **Income taxes** | **13,419** | **11,864** | **(7,021)** | **18,262** |
| **Depreciation** | **5,338** | **6,353** | **24** | **11,715** |
| **Amortization** | **18** | **2,492** | **-** | **2,510** |
| **EBITDA** | **59,587** | **57,975** | **(19,294)** | **98,268** |
| **Add/(deduct):** |  |  |  |  |
| **Intercompany interest expense/(income)** | **(4,525)** | **(1,620)** | **6,145** | **-** |
| **Interest income** | **(61)** | **(31)** | **-** | **(92)** |
| **Stock option expense** | **-** | **-** | **6,106** | **6,106** |
| **Direct costs related to COVID-19** | **1,753** | **553** | **38** | **2,344** |
| **Long-term incentive compensation** | **-** | **-** | **1,893** | **1,893** |
| **Adjusted EBITDA** | **$56,754** | **$56,877** | **$(5,112)** | **$108,519** |
|  |  |  |  | Chemed |
| For the three months ended March 31, 2020 | VITAS | Roto-Rooter | Corporate | Consolidated |
| Net income/(loss) | $41,279 | $24,322 | $(9,710) | $55,891 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 45 | 102 | 828 | 975 |
| Income taxes | 13,739 | 7,784 | (8,492) | 13,031 |
| Depreciation | 5,474 | 5,878 | 36 | 11,388 |
| Amortization | 18 | 2,459 | - | 2,477 |
| EBITDA | 60,555 | 40,545 | (17,338) | 83,762 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (4,386) | (1,349) | 5,735 | - |
| Interest income | (68) | (40) | - | (108) |
| Stock option expense | - | - | 5,045 | 5,045 |
| Direct costs related to COVID-19 | 973 | 861 | - | 1,834 |
| Long-term incentive compensation | - | - | 1,821 | 1,821 |
| Medicare cap sequestration adjustment | 675 | - | - | 675 |
| Adjusted EBITDA | $57,749 | $40,017 | $(4,737) | $93,029 |

*RECONCILIATION OF ADJUSTED NET INCOME*

*(in thousands, except per share data)(unaudited)*

|  | Three Months Ended March 31, 2021 | 2020 |
| --- | ---: | ---: |
| Net income as reported | **$65,400** | $55,891 |
| Add/(deduct) pre-tax cost of: |  |  |
| Stock option expense | **6,106** | 5,045 |
| Amortization of reacquired franchise agreements | **2,352** | 2,352 |
| Direct costs related to COVID-19 | **2,344** | 1,834 |
| Long-term incentive compensation | **1,893** | 1,821 |
| Medicare cap sequestration adjustment | **-** | 675 |
| Add/(deduct) tax impacts: |  |  |
| Tax impact of the above pre-tax adjustments (1) | **(2,487)** | (2,350) |
| Excess tax benefits on stock compensation | **(3,238)** | (4,553) |
| Adjusted net income | **$72,370** | $60,715 |
| Diluted Earnings Per Share As Reported |  |  |
| Net income | **$4.01** | $3.38 |
| Average number of shares outstanding | **16,310** | 16,516 |
| Adjusted Diluted Earnings Per Share |  |  |
| Adjusted net income | **$4.44** | $3.68 |
| Adjusted average number of shares outstanding | **16,310** | 16,516 |
| (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. |  |  |

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*OPERATING STATISTICS FOR VITAS SEGMENT*

*(unaudited)*

| OPERATING STATISTICS Net revenue ($000) | Three Months Ended March 31, 2021 | 2020 |
| --- | ---: | ---: |
| Homecare | **$263,754** | $271,762 |
| Inpatient | **29,156** | 32,482 |
| Continuous care | **27,349** | 40,555 |
| Other | **2,938** | 3,147 |
| Subtotal | **$323,197** | $347,946 |
| Room and board, net | **(2,665)** | (3,381) |
| Contractual allowances | **(3,244)** | (4,149) |
| Medicare cap allowance | **(1,500)** | (2,500) |
| Total | **$315,788** | $337,916 |
| Net revenue as a percent of total before Medicare cap allowances |  |  |
| Homecare | **81.6%** | 78.1% |
| Inpatient | **9.0** | 9.3 |
| Continuous care | **8.5** | 11.7 |
| Other | **0.9** | 0.9 |
| Subtotal | **100.0** | 100.0 |
| Room and board, net | **(0.8)** | (1.0) |
| Contractual allowances | **(1.0)** | (1.2) |
| Medicare cap allowance | **(0.5)** | (0.7) |
| Total | **97.7%** | 97.1% |
| Days of care |  |  |
| Homecare | **1,329,892** | 1,364,746 |
| Nursing home | **232,783** | 303,374 |
| Respite | **4,840** | 6,692 |
| Subtotal routine homecare and respite | **1,567,515** | 1,674,812 |
| Inpatient | **27,674** | 32,348 |
| Continuous care | **29,300** | 41,373 |
| Total | **1,624,489** | 1,748,533 |
| Number of days in relevant time period | **90** | 91 |
| Average daily census (days) |  |  |
| Homecare | **14,777** | 14,997 |
| Nursing home | **2,586** | 3,334 |
| Respite | **54** | 74 |
| Subtotal routine homecare and respite | **17,417** | 18,405 |
| Inpatient | **307** | 355 |
| Continuous care | **326** | 455 |
| Total | **18,050** | 19,215 |
| Total Admissions | **18,135** | 18,603 |
| Total Discharges | **18,516** | 18,196 |
| Average length of stay (days) | **94.4** | 90.7 |
| Median length of stay (days) | **12.0** | 14.0 |
| ADC by major diagnosis |  |  |
| Cerebro | **35.9%** | 35.9% |
| Neurological | **22.1** | 21.4 |
| Cancer | **12.2** | 12.7 |
| Cardio | **15.8** | 15.9 |
| Respiratory | **7.8** | 8.3 |
| Other | **6.2** | 5.8 |
| Total | **100.0%** | 100.0% |
| Admissions by major diagnosis |  |  |
| Cerebro | **21.4** | 21.1% |
| Neurological | **12.3** | 12.5 |
| Cancer | **25.0** | 28.3 |
| Cardio | **14.2** | 15.1 |
| Respiratory | **11.0** | 12.2 |
| Other | **16.1** | 10.8 |
| Total | **100.0%** | 100.0% |
| Estimated uncollectible accounts as a percent of revenues | **1.0%** | 1.2% |
| Accounts receivable -- |  |  |
| Days of revenue outstanding- excluding unapplied Medicare payments | **37.8** | 33.9 |
| Days of revenue outstanding- including unapplied Medicare payments | **26.9** | 26.1 |

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

## Market risk

As filed, 572 characters.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At March 31, 2021, the Company had no variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

## Controls and procedures

As filed, 900 characters.

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 141 characters.

There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Filed Apr 30, 2021.
Source: SEC EDGAR, the filing index for accession 0000019584-21-000009. Last ingested by Listed: Nov 14, 2026, 12:29 ET. No prices; not investment advice.
